Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar ryanman000 (91.35) Submitted: 8/31/2011 3:46:45 PM : Outperform Start Price: $12.30 DNDN Score: -50.09

Time machine investmentCounterpoint: 700% share dilution

Featured Broker Partners


Advertisement